Participated · Series A · Aug 2026

Infinimmune uses its Anthrobody platform to screen millions of single memory B cells across hundreds of targets to identify naturally paired human antibodies, then applies its GLIMPSE antibody language models to guide optimisation for potency, specificity, half-life and developability. Its lead programmes are IFX-101, a monoclonal antibody targeting interleukin-22 described as a potential first-in-class candidate, and IFX-201, which targets interleukin-13 as a potential best-in-class option for atopic dermatitis. The company expects first-in-human studies for both programmes to begin in 2027 and is advancing additional antibody programmes derived from its human-first discovery approach. Financially, Infinimmune raised $75 million in a Series A co-led by Regeneron Ventures and Playground Global, and earlier support includes ongoing backing from Playground Global since founding. In March 2026 it entered a multi-target collaboration with Merck that includes up to about $838 million in upfront and potential milestone payments, which the company cites as validation of its platform and a potential commercial route.

Participated · Series B · Mar 2026

Unnatural Products has built an integrated discovery platform to engineer synthetic macrocyclic peptides at scale, combining computational design, automated chemistry, and high-throughput biological testing. The company positions macrocyclic peptides as a modality that can marry biologics-level selectivity with small-molecule delivery properties, including potential oral delivery and cell permeability. Its pipeline targets cardiometabolic, inflammatory, and immunological diseases, and the company is advancing lead programs toward clinical development. Unnatural Products has established collaborations with pharma and biotech partners including Novartis, Merck, BridgeBio and argenx; the Novartis deal includes up to $100 million upfront and up to $1.7 billion in milestones. The recent $45 million Series B will fund further platform development and pipeline advancement. The company is headquartered in Santa Cruz, California.

Participated · Seed · Nov 2025

Cassidy Bio is developing what it claims is the first AI-driven genomic foundation model that integrates proprietary wet-lab data, population-scale genomics and advanced machine learning to optimize the selection of guides, enzymes and delivery modalities for gene-editing therapeutics. By replacing today’s slow, trial-and-error approach with large-scale in-silico prediction and validation, the platform aims to increase precision, speed and clinical confidence in CRISPR-based drug development. The Tel Aviv-based startup’s end-to-end workflow ranks potential designs by safety and efficacy, with the goal of enabling reliable gene-editing medicines at scale rather than isolated successes. Its founding team combines serial biotech entrepreneur and CEO Rom Kshuk, CRISPR scientist Ayal Hendel, PhD, and AI specialist Yaniv Shmueli, PhD, and is supported by a scientific advisory board featuring former leaders from Editas Medicine, UPenn, Ultima Genomics and Intellia Therapeutics. Cassidy Bio plans to use newly raised capital to further train and validate its genomic foundation model and expand its wet-lab capabilities. To date, the company has secured $8 million in seed financing; no revenue, user or clinical metrics have yet been disclosed.

Participated · Series C · Sep 2025

Octave Bioscience is a commercial-stage precision care company whose flagship product is the Octave MSDA test, a multi-analyte blood-based assay for monitoring MS disease activity. The company reports broad physician adoption with over 325 prescribers, more than 19,000 patient tests delivered to date, and in-network reimbursement covering over 75 million contracted lives at favorable rates. Proceeds from the recent financings will support continued commercialization of the MSDA test and advancement of the company’s Parkinson’s disease pipeline. Octave describes its platform as providing quantitative, clinically actionable insights to improve disease monitoring and treatment decisions. The company also notes a partnership with the Michael J. Fox Foundation on Parkinson’s disease efforts. Octave is based in Menlo Park, Calif. Octave Bioscience is a commercial-stage precision-medicine company that delivers a Precision Care Solution for multiple sclerosis and other neurodegenerative diseases. Its solution includes the Octave MSDA Test, a multivariate blood test for multiple sclerosis, enhanced MRI analytics and protocols, and a clinical care program that connects patients with MS-certified nurse care partners. The Precision Care Solution is currently in use in over 50 clinics across the United States. Octave plans to expand its biomarker-based approach into Parkinson’s disease and will use a $10M grant from The Michael J. Fox Foundation to discover, develop, and validate a custom multiplexed protein biomarker panel to measure Parkinson’s disease activity and progression in the clinic. The company was selected for the MJFF grant based on its track record in biomarker research and prior commercialization of a multiplexed assay panel for multiple sclerosis. Octave combines blood biomarkers, imaging, and clinical insights to provide longitudinal and holistic patient metrics intended to enable informed care, shared decision making, and better patient outcomes. Octave offers a multimodal precision care solution that combines blood biomarkers, expanded MRI analytics, and clinical insights to objectively measure MS disease activity, progression, and severity. Its platform includes the first multivariate blood test for MS disease activity, enhanced imaging protocols, and a clinical care program linking patients with MS nurse practitioners in real time. Octave commercially launched in late 2022 and is in use at multiple MS Centers of Excellence, academic centers, and high-volume independent clinics. The company is expanding physician partnerships and providing capabilities to pharma companies and health plans. Octave is also committed to building collaborations across a broader range of neurodegenerative diseases, including Parkinson’s and Alzheimer’s. Financially, the company announced a $30M extension to its Series B to accelerate commercialization and broaden patient access to its solution. Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with multiple sclerosis (MS). The platform integrates multiple layers of insight: blood-based biomarkers to assess inflammation and immune modulation, advanced MRI readings and interpretation for CNS-level insights, and real-time symptom tracking via mobile tools, sensors and wearables. All data are integrated into protocols, supported by decision‑support tools and presented in a dashboard that enables individual and population views for better stratification and contextual interventions. Octave plans to use these capabilities to provide measurement and management tools for physicians and precision tools and services for pharmaceutical companies to better characterize therapies and optimize pipeline programs. The company emphasizes longitudinal perspectives on disease progression and aims to expand the platform’s applicability across a broad range of neurodegenerative diseases. Octave is headquartered in Menlo Park, California. Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with multiple sclerosis. The platform integrates blood-based biomarkers, enhanced MRI insights, patient monitoring via mobile tools and sensors, and a nurse-led care partner program to produce objective, quantitative measurements. Those measurement layers feed into care pathway models, analytical support systems, decision-support tools and a dashboard to provide longitudinal, population and individual views for clinicians. Octave plans to expand clinical data, initiate early commercial activities, and begin serving neurologists, MS patients and health plans. The company highlights potential application beyond MS to Parkinson’s disease, ALS and Alzheimer’s disease. Octave Bioscience is headquartered in Menlo Park, California.

Led · Equity · Jun 2025

PreciseDx develops PreciseBreast, an AI-enabled diagnostic that uses the company’s OncoIntelligence platform to inform breast cancer care. PreciseBreast combines seven morphologic features and four clinical factors into a single OncoIntelligence Score (0–100) to stratify recurrence risk and support care planning within hours. The test has been clinically validated in more than 3,000 breast cancer cases to reliably separate patients into two cohorts based on six‑year recurrence risk. The company says the platform could extend to treatment guidance for other solid tumor types. PreciseDx announced an $11 million financing, bringing total funding to over $43 million, to support ongoing clinical data collection, commercial expansion and planning for a 2026 commercial launch. The company also announced two executive hires: Eric Converse as CEO and Ed Sitar as CFO; founder Carlos Cordon‑Cardo retains a financial interest. PreciseDx is an NYC-based innovator in oncology diagnostics that leverages artificial intelligence for morphology-driven disease analysis. Its platform combines AI with the patented Morphology Feature Array® (MFA) to generate actionable intelligence for decision-making across the cancer care continuum. The company's flagship offering is PreciseBreast™, a risk assessment intended to inform breast cancer care and screening decisions. PreciseDx plans to use new funding to expand commercialization of PreciseBreast™. Financially, PreciseDx recently closed a $20.7M Series B to support those commercialization efforts. The company has completed analytical and clinical validation studies, received CLIA Standard approval and CLEP NYSDOH review for PreciseBreast™, and had a Cost Impact Study published in the Journal of Medical Economics. PreciseDx has added collaborations with UCLA, COTA, Baptist Health South Florida, and Baylor Scott & White Health.